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ABSTRACT 34	
GBF1 has emerged as a host factor required for the replication of positive-sense single-35	
stranded RNA viruses of different families, but its mechanism of action is still unknown. 36	
GBF1 is a guanine-nucleotide exchange factor for Arf family members. Recently, we 37	
identified Arf4 and Arf5 (class II Arfs), as host factors required for the replication of hepatitis 38	
C virus (HCV), a GBF1-dependent virus. To assess if a GBF1/class II Arfs pathway is 39	
conserved among positive-sense single-stranded RNA viruses, we investigated yellow fever 40	
virus (YFV), Sindbis virus (SINV), coxsackievirus B4 (CVB4) and human coronavirus 229E 41	
(HCoV-229E). We found that GBF1 is involved in the replication of these viruses. However, 42	
using siRNA or CRISPR-Cas9 technologies, the depletion of Arf1, Arf3, Arf4 or Arf5 had no 43	
impact on viral replication. In contrast, the depletion of Arfs pairs suggested that class II Arfs 44	
could be involved in HCoV-229E, YFV and SINV infection, as for HCV, but not in CVB4 45	
infection. In addition, another Arf pair, Arf1 and Arf4, appears essential for YFV and SINV 46	
infection, but not for other viruses. Finally, CVB4 infection was not inhibited by any 47	
combination of Arf depletion. We conclude that the mechanism of action of GBF1 in viral 48	
replication appears not to be conserved, and that a subset of positive-sense single-stranded 49	
RNA viruses from different families might require class II Arfs for their replication. 50	
  51	
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INTRODUCTION 52	
Positive-sense, single-stranded RNA viruses ((+)RNA viruses) replicate their genome in the 53	
cytoplasm of their host cell. Their RNA-dependent RNA polymerase and other non-structural 54	
proteins implicated in the replication are found in association with cellular membranes. For a 55	
number of (+)RNA viruses, intracellular membranes of the host cells are rearranged during 56	
replication and viral replication complexes are associated with these membrane 57	
rearrangements. The morphology and origin of these membrane rearrangements appear to 58	
vary for different viruses. However, it is possible that some conserved cellular pathways are 59	
redirected during the replication of different viruses for the formation and functioning of these 60	
membranous replication complexes. 61	
GBF1 has recently emerged as a host factor involved in the replication of (+]RNA viruses of 62	
the Picornaviridae [1-3], Coronaviridae [4], Flaviviridae [5,6] and Hepeviridae [7] families. 63	
GBF1 is a brefeldin A (BFA)-sensitive guanine nucleotide exchange factor (GEF) of Arf 64	
family members [8]. Through Arf1 activation, it participates to the regulation of COP-I-65	
dependent vesicular transport, phospholipid metabolism, actin cytoskeleton dynamics at the 66	
Golgi, and lipid droplet metabolism [9,10]. GBF1 has 6 conserved domains [11]. Its Arf-GEF 67	
activity is catalyzed by the Sec7 domain and is selective for class I Arfs (Arf1-3) and class II 68	
Arfs (Arf4 and Arf5) [8,12]. The functions of the other conserved domains are less defined 69	
[11,13]. 70	
Little is known about the mechanism of action of GBF1 in viral infections. Its Arf-GEF 71	
activity appears to be of special importance at the onset of the replication of different viruses 72	
[4-7]. Accordingly, GBF1 is temporally recruited to replication complexes at early times of 73	
poliovirus replication, but not later on [14]. However, its Arf-GEF activity is not required for 74	
the formation of replication complexes-associated membrane rearrangements [1,4,5], 75	
suggesting that GBF1 is rather involved in a post-formation step of membrane-associated 76	
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replication complexes. It has been proposed that GBF1 function in viral infections could be 77	
related to the regulation of COP-I, a molecular machinery involved in intracellular transport, 78	
which has also been reported to be required for the replication of several (+)RNA viruses [15-79	
19]. GBF1 regulates COP-I vesicle formation by stimulating COP-I recruitment to Golgi 80	
membranes through Arf1 activation in a BFA-sensitive manner [9,10]. By analogy, the BFA 81	
sensitivity of viral replication has been viewed as an argument for Arf1 involvement. In 82	
support to this hypothesis, Arf1 [20], or both Arf1 and Arf3 [3] are activated during 83	
enterovirus infection, and siRNA-mediated depletion of Arf1 [4,21] or of both Arf1 and Arf3 84	
[3] impairs the replication of diverse (+)RNA viruses. However, an experimental 85	
demonstration of the existence of a GBF1-Arf1-COP-I pathway involved in viral replication 86	
is still lacking. During poliovirus infection, GBF1 is transiently recruited to replication 87	
complexes, but this recruitment is not coupled to COP-I recruitment [14]. Moreover, during 88	
poliovirus replication, GBF1 function does not depend on its catalytic Sec7 domain and 89	
therefore on its Arf-GEF activity [22], indicating a mechanism of action unrelated to Arf1 90	
activation. 91	
We previously showed that GBF1 is critical to the replication of hepatitis C virus (HCV) [5], 92	
and that its Arf-GEF activity is essential for regulating HCV replication [23]. However, GBF1 93	
function in HCV replication is not mediated by Arf1, and is distinct from its regulatory 94	
functions of the cellular secretory pathway and of the morphology of the Golgi complex, two 95	
cellular processes that are mediated by COP-I. We found that different pairs of Arf proteins 96	
are involved in these two functions of GBF1. The Arf1/Arf4 pair is involved in the regulation 97	
of the secretory pathway and the Arf4/Arf5 pair in the replication of HCV [23]. In this study 98	
we compared the requirement of Arfs for the replication of a series of GBF1-dependent 99	
(+)RNA viruses from different families.  100	
 101	
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 102	
RESULTS 103	
BFA sensitivity of (+)RNA viruses 104	
To probe for GBF1 dependency, we made use of BFA, which inhibits GBF1 and two related 105	
Arf-GEFs, named BIG1 and BIG2. In addition to HCV, we selected viruses from different 106	
families of (+)RNA viruses, namely yellow fever virus (YFV, Flaviviridae), human 107	
coronavirus 229E (HCoV-229E, Coronaviridae), coxsackievirus B4 (CVB4, Picornaviridae), 108	
and Sindbis virus (SINV, Togaviridae). We also included human adenovirus-5, a DNA virus, 109	
as a negative control. Cells were infected in the presence of increasing doses of BFA. To 110	
avoid cell toxicity, BFA treatment was restricted to 8 hours of contact, when the infection was 111	
scored later than 8 hours post-infection (hpi) (adeno, HCoV-229E, YFV, HCV). As 112	
previously shown [5], adenovirus was not inhibited by BFA. In contrast, all RNA viruses 113	
tested were sensitive to treatment with 0.1 to 10 µg/ml BFA in a dose-dependent manner (fig. 114	
1a). However, the extent of inhibition was different between viruses. When comparing the 115	
inhibition of infection at 1 µg/ml BFA, CVB4 and HCoV-229E appeared the most sensitive 116	
viruses (~99% inhibition) and SINV the least one (62% inhibition), HCV and YFV having 117	
intermediate sensitivities (~97% and ~88% inhibition, respectively). It is noteworthy that this 118	
difference of sensitivity between viruses is only visible in the amplitude of the inhibitory 119	
response, but not in the range of inhibitory doses of BFA. For all viruses, the first inhibitory 120	
dose was 0.1 µg/ml. No inhibition could be observed with 0.01 µg/ml BFA for any virus. 121	
Such a similar range of inhibitory doses observed with all RNA viruses suggests a similar 122	
mode of action of BFA against all these viruses.  123	
An MTS assay was performed to quantify the impact of BFA toxicity on Huh-7 cells (fig. 1b). 124	
Two protocols were used to assess different protocols of infection. The assay was performed 125	
either after 6 hours of contact in the presence of BFA, or after 8 hours of contact followed by 126	
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22 hours without BFA. These two protocols correspond to the shortest (CVB4 and SINV) and 127	
longest (HCV) infection periods used for quantifying BFA inhibition of viral infections. The 128	
only experimental condition showing an inhibition of cell growth or metabolism was with 8 129	
hours incubation with 10 µg/ml BFA, followed by 22 hours without BFA. However, the 130	
decrease was not in the same proportion as viral infection inhibitions measured in the same 131	
condition. With 1 µg/ml BFA, the inhibition of cell growth was minimal (~20% decrease), 132	
whereas the inhibition of viral infections was close to maximal. These results, together with 133	
the absence of inhibition of adenovirus infection, indicate that the inhibition of (+)RNA 134	
viruses infections could not be explained by BFA toxicity.  135	
 136	
GBF1 dependency of (+)RNA viruses 137	
Because GBF1 is not the only target of BFA, we also assessed the impact of BFA on viral 138	
infections in R1 cells. R1 cells are Huh-7-derived cells that have a point mutation in one copy 139	
of the GBF1 gene [24]. This mutation replaces the methionine residue 832 in the catalytic 140	
Sec7 domain by a leucine, a substitution that dramatically decreases BFA binding to GBF1 141	
[25]. Since the two other BFA-sensitive Arf-GEFs, BIG1 and BIG2, are not mutated in R1 142	
cells, any effect of a BFA treatment can be attributed to the inhibition of BIG1 and/or BIG2, 143	
but not of GBF1. Inversely, an action of BFA in Huh-7 cells that is not reproduced in R1 cells 144	
indicates an involvement of GBF1. We infected R1 cells in the presence of BFA and 145	
quantified infections as we did before in Huh-7 cells. A ~100 fold decrease of BFA sensitivity 146	
of all viral infections was observed (fig. 2a). The only inhibitory dose was 10 µg/ml, and its 147	
impact on infections was similar to that observed with 0.1 µg/ml in Huh-7 cells. This shift in 148	
BFA sensitivity between R1 and parental Huh-7 cells indicates an involvement of GBF1 in 149	
viral infections. 150	
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To further assess the importance of GBF1 in the infection of BFA-sensitive RNA viruses, we 151	
used golgicide A (GCA), which is a specific inhibitor of GBF1, with no action on other BFA 152	
targets [26]. GCA inhibited all BFA-sensitive viruses (fig. 2b), confirming that the observed 153	
inhibition of infection by BFA was only due to its action on GBF1. Again, CVB4 and HCoV-154	
229E were the two most affected viruses. As for BFA treatments, a small decrease in cell 155	
growth was also observed with an 8-hour treatment with GCA followed by 22 hours with no 156	
inhibitor and, to a lesser extent, with a 6-hour treatment (fig. 2c). These results confirm the 157	
implication of GBF1 in the infection of all RNA viruses tested in this study. 158	
We next investigated which step of the viral life cycle is affected by GBF1 inhibition. GBF1 159	
was previously shown to be involved in a post-entry step of the HCV life cycle [5]. CVB4 160	
and HCoV-229E, the two viruses the most affected by BFA, were investigated. To test GBF1 161	
involvement during virus entry, BFA was added to cells during virus contact and removed 162	
post-entry. To test GBF1 involvement at a post-entry step, cells were infected in the absence 163	
of BFA, and BFA was added during 6 hours after virus removal. For both viruses, the 164	
infection was inhibited when BFA was present at the post-entry step, but much less affected 165	
when BFA was present at the entry step (fig. 3). These results indicated that GBF1 is likely 166	
involved in a post-entry step of the life cycle of these (+)RNA viruses. 167	
 168	
Involvement of Arf family members in the infection of (+)RNA viruses 169	
We next assessed if the requirement of GBF1 for (+)RNA virus infection translated into an 170	
involvement of Arfs. Arf proteins potentially regulated by GBF1 and sensitive to BFA and 171	
GCA, namely Arf1, Arf3, Arf4 and Arf5 (human cells have no Arf2), were depleted with 172	
pools of synthetic siRNAs. The extent and the specificity of depletion were evaluated using a 173	
set of antibodies specific for each Arf protein (fig. 4a). Each siRNA pool specifically depleted 174	
the targeted protein with minimal impact on the expression of other Arfs (fig. 4b), except for 175	
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two effects: Arf4 was overexpressed in cells depleted of Arf1, and Arf3 expression was 176	
slightly reduced in cells depleted of Arf4 (fig. 4c). Arf4 overexpression in Arf1-depleted cells 177	
was previously detected at the mRNA level [23], suggesting that these two Arf proteins are 178	
functionally linked. Other variations of expression levels appeared non-significant.  179	
When siRNA-treated cells were infected, an inhibition of infection of approximately 10-30% 180	
was measured for all viruses and for all Arf proteins (fig. 4d), except for CVB4, which was 181	
not impacted by Arf4 and by Arf5 depletions. The inhibition of HCoV-229E and HCV 182	
infection imposed by Arf1, Arf4 and Arf5 siRNAs appeared significant, but most of the other 183	
inhibitions were not. Such a moderate and non-specific inhibition of infection in cells 184	
depleted of each Arf protein was previously observed with HCV [23]. When Huh-7 cells were 185	
depleted of two Arf proteins simultaneously, two pairs of siRNA pools induced an inhibition 186	
of infection larger than the ones observed with single depletions (fig. 4e). SINV and YFV 187	
infections were inhibited by the depletion of Arf1 and Arf4 (80% and 92% inhibition, 188	
respectively). In addition, HCV, SINV and YFV infections were inhibited in cells 189	
simultaneously depleted of Arf4 and Arf5 (61%, 70% and 54% inhibition, respectively). 190	
HCoV-229E infection also appeared to be reduced in cells depleted of this pair of Arfs, but 191	
the inhibition was less dramatic (43% inhibition). In addition, similar inhibitions were also 192	
observed with other Arf pairs for this virus. These inhibitions of infection were not correlated 193	
to a loss of viability of the cells (fig. 4f). It is noteworthy that CVB4 infection was not 194	
strongly affected by any Arf pair depletion. This lack of inhibition was confirmed by 195	
immunoblot analysis of VP1 expression (fig. 4g). 196	
To confirm the results obtained using siRNAs, we used CRISPR-Cas9 technology to generate 197	
knockout (KO) cells. One Arf4KO, one Arf5KO and three Arf1KO cell lines were generated. 198	
To avoid biases resulting from the use of clones, we used the whole population of cells 199	
transfected with CRISPR-Cas9 constructs in each case. A small amount of residual expression 200	
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of targeted proteins of 0 to 20% was measured for each cell line (fig. 5a). This residual 201	
expression likely resulted from the presence of a small amount of cells expressing the targeted 202	
protein. No major impact on the expression of other Arfs was observed, except for a slight 203	
decrease in Arf5 expression in the Arf1KO cell line 1.3, which was not observed for the two 204	
other Arf1KO cell lines (fig. 5b). 205	
ArfKO cell lines were infected with HCoV-229E, HCV, SINV or YFV, the four viruses 206	
impacted in siRNA experiments. The infections of these four viruses were marginally affected 207	
in the three Arf1KO cell lines. They were inhibited by 20-30% in the Arf5KO cell line 5.1. In 208	
the Arf4KO cell line 4.1, HCV infection was inhibited by 20% and the infections by HCoV-209	
229E, SINV and YFV were inhibited by ~50% (fig. 5c). These results confirmed the lack of 210	
inhibition of HCV infection by any single Arf depletion, and revealed an importance of Arf4 211	
in HCoV-229E, SINV and YFV infections that was not detected in siRNA experiments. 212	
We next tried to generate double KO cell lines by transfecting Arf4 CRISPR-Cas9 constructs 213	
in the Arf5KO cell line or Arf5 CRISPR-Cas9 constructs in the Arf4KO cell line. 214	
Unfortunately, most cells died during the selection, and the few surviving cells turned out not 215	
to be double KO (data not shown). This indicates that a permanent invalidation of both class 216	
II Arf genes is lethal for Huh-7 cells. Therefore, we used siRNAs to transiently deplete Arf 217	
proteins in ArfKO cell lines. Again, we observed a strong toxicity of siRNAs to Arf1 or to 218	
Arf5 transfected in the Arf4KO cell line. On the other hand, Arf4 depletion by siRNA 219	
transfection was also toxic in Arf1KO cells, but not in Arf5KO cells. An MTS assay 220	
confirmed the absence of toxicity of Arf4 siRNA transfection in the Arf5KO cell line 5.1 (fig. 221	
6a). 222	
Therefore, we used this experimental setup (siRNA-mediated depletion of Arf4 in Arf5KO 223	
cells) to confirm the importance of the pair of class II Arfs in viral infections. As controls, we 224	
used a non-targeting siRNA, as for experiments in parental Huh-7 cells, and also the Arf5 225	
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siRNA pool, which should have no impact in Arf5KO cells. As a control cell line, we used a 226	
cell line selected after transfection of a CRISPR-Cas9 construct expressing no guide RNA. 227	
The depletion of Arf4 and Arf5 was confirmed by immunobloting (fig. 6b). Arf5 was 228	
undetectable in cells transfected with Arf5 siRNA and in Arf5KO cells, and was not affected 229	
by the depletion of Arf4 in control cells. Arf4 expression was reduced to ~30% in both cell 230	
lines after transfection of Arf4 siRNA. 231	
siRNA-transfected control and Arf5KO cells were infected with HCoV-229E, HCV, SINV 232	
and YFV. As expected from results of previous double depletions by siRNA, HCoV-229E, 233	
HCV and SINV infections were strongly inhibited (85%, 89% and 83% inhibition, 234	
respectively) (fig. 6c). In contrast, YFV infection was less impacted (53% inhibition). In all 235	
other conditions, viral infections were inhibited by less than 40%, except in Arf5KO cells 236	
transfected with Arf5 siRNAs, which surprisingly displayed an inhibition of almost 50% of 237	
HCV and SINV infections, likely resulting from off-target effects. All together, these results 238	
confirmed the importance of class II Arfs for infection by HCV [23] and by HCoV-229E, 239	
SINV and YFV, as previously observed with double siRNAs transfection-based experiments. 240	
 241	
DISCUSSION 242	
In this study, we investigated whether the function of class II Arfs is conserved in infections 243	
of GBF1-dependent (+)RNA viruses. GBF1 has been reported to be required for the 244	
replication of different viruses, but its function is still not understood. Recently, we found that 245	
the function of GBF1 in HCV replication differs from its function in the early secretory 246	
pathway [24]. Whereas the effect of GBF1 inhibition or depletion on the secretion of albumin 247	
and VLDL and on the Golgi morphology is phenocopied by simultaneously depleting both 248	
Arf1 and Arf4, the depletion of this pair of Arfs has no impact on HCV infection [23]. In 249	
contrast, the impact of GBF1 inhibition or depletion on HCV replication is phenocopied by 250	
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the depletion of another pair of Arfs. HCV replication is specifically inhibited by 251	
simultaneously depleting Arf4 and Arf5. Interestingly, the depletion of this pair of Arfs has 252	
no impact on the secretion of albumin or VLDL. Cells depleted of Arf4 and Arf5 accumulate 253	
enlarged lipid droplets, suggesting a function related to the regulation of lipid metabolism or, 254	
at least, to the morphology of these organelles, which are known to depend on GBF1 for their 255	
metabolism [9,10]. Therefore, different GBF1 functions appear to be mediated by different 256	
pairs of Arfs. This is in line with a previous report that the depletion of different Arf pairs 257	
results in different specific phenotypes on secretory and endosomal compartments [27], which 258	
are collectively observed upon BFA treatment of the cells. All these observations suggest that 259	
different pairs of Arfs could mediate the different cellular functions that are regulated by 260	
GBF1, BIG1 and BIG2, the three BFA-sensitive Arf-GEFs. 261	
The function of the class II Arf pair in virus infection appears to be partly conserved among 262	
viruses from different families. Their simultaneous depletion inhibited infection by HCV, 263	
HCoV-229E, SINV and YFV, but not by CVB4. Interestingly, all these viruses also depend 264	
on GBF1 for their replication, suggesting the existence of a GBF1-Arf4/5 pathway 265	
requirement for some but not all (+)RNA viruses. These inhibitions were also observed to 266	
some extent with the Arf4KO but not the Arf5KO cell line, suggesting a major importance of 267	
Arf4, which had not been observed with siRNA-mediated depletions of individual Arf 268	
proteins. 269	
We also tried to confirm the contribution of class II Arfs with double KO cells. Unfortunately, 270	
the double KO was not viable, when each single KO was, suggesting that class II Arfs 271	
collectively fulfil a vital function in Huh-7 cells. We also observed a great reduction of 272	
viability in Arf4KO cells transfected with Arf5 siRNA. Nevertheless, the siRNA-mediated 273	
depletion of Arf4 in Arf5KO cells turned out to be not toxic. This difference probably 274	
resulted from a less pronounced down-regulation imposed by Arf4 siRNA, than by Arf5 275	
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siRNA. Therefore, the transfection of Arf4 siRNA in Arf5KO cells probably resulted in 276	
residual Arf4 expression levels compatible with cell survival. This allowed us to confirm the 277	
inhibition of HCV, HCoV-229E, SINV and YFV infections in cells depleted of both class II 278	
Arfs. Class II Arfs were previously reported to be implicated in the dengue virus life cycle, 279	
and more precisely in the assembly/secretion step, but the replication step was not 280	
investigated [28]. It would have been interesting to confirm that the depletion of class II Arfs 281	
actually affects the replication step of the life cycle of HCoV-229E, SINV and YFV, as it 282	
does for HCV [23]. Unfortunately, we do not have the tools to address this question. 283	
Nevertheless, we have shown that GBF1 is implicated in HCV replication [5] and in a post-284	
entry step of the life cycle of HCoV-229E and CVB4 (this study). 285	
In addition to the Arf4/Arf5 pair, YFV and SINV were also sensitive to the simultaneous 286	
depletion of Arf1 and Arf4. As this Arf pair is involved in the regulation of the secretory 287	
pathway [23,27], this suggests an involvement of this pathway in the life cycle of these 288	
viruses. Currently, we do not know which step of their life cycle is actually impacted by the 289	
depletion of this Arf pair. An entry inhibition can be hypothesized, resulting from a default of 290	
expression of specific receptors at the cell surface. Alternatively, we cannot rule out the 291	
possibility of an inhibition of the replication step. The Arf1/Arf4 pair has been previously 292	
reported to be involved in the localization of the capsid protein to lipid droplets in dengue 293	
virus-infected cells [29]. 294	
In contrast, CVB4 infection was not inhibited in cells depleted of both Arf4 and Arf5, nor of 295	
any other Arf pair, although it was inhibited by BFA in a GBF1-dependent manner. This 296	
suggests that the function of GBF1 in CVB4 infection could be unrelated to its Arf-GEF 297	
activity. Previously, a study by Lanke et al. demonstrated the implication of GBF1, but could 298	
not find any implication of Arfs, in the replication of CVB3 [2]. A sec7-independent GBF1 299	
function has also been reported for poliovirus infection [22]. In contrast, the replication of 300	
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enterovirus 71 has been reported to depend on the pair of class I Arfs, Arf1 and Arf3 [3]. 301	
Further studies will be necessary to assess if CVB4, and more generally which other 302	
enteroviruses use a Sec7-independent function of GBF1 and what is the mechanism of action. 303	
In conclusion, this study confirms and extends the implication of class II Arfs in the infection 304	
of different (+)RNA viruses. Cellular pathways specifically controlled by class II Arfs are 305	
currently unknown. Arf4 has been proposed to be part of a Golgi stress-response pathway 306	
[30]. This function of Arf4 requires GBF1, but is not linked to Arf5. Collectively, class II 307	
Arfs are not involved in the regulation of the secretory pathway [23,27]. They fulfil a vital 308	
function in Huh-7 cells, and they also appear to be involved in regulating the morphology of 309	
lipid droplets. However, we still do not know whether these two functions are related to each 310	
other. Future work is required to decipher pathways specifically regulated by class II Arfs and 311	
to identify effectors implicated in these pathways, which could be interesting new targets for 312	
developing antiviral therapies. 313	
 314	
 315	
METHODS 316	
Reagents.  Dulbecco's modified Eagle's medium (DMEM), phosphate-buffered saline (PBS) 317	
and 4',6-diamidino-2-phenylindole (DAPI) were purchased from Life Technologies. Goat and 318	
fetal calf sera (FCS) were from Eurobio. Golgicide A and Mowiol 4-88 were from 319	
Calbiochem. Protease inhibitors cocktail (Complete) was from Roche. Other chemicals were 320	
from Sigma. 321	
Antibodies.  Mouse anti-HCV E1 mAb A4 [31] and mouse anti-YFV E mAb 2D12 (anti-E, 322	
ATCC CRL-1689) were produced in vitro by using a MiniPerm apparatus (Heraeus). Mouse 323	
anti-enterovirus VP1 mAb (clone 5-D8/1) was from DAKO. Mouse anti-Arf1 mAb 1A9/5 324	
was from Santa Cruz Biotechnology. Mouse anti-Arf3 mAb was from BD Biosciences. 325	
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Rabbit anti-human Arf4 mAb EPR12133B was from Abcam. Mouse anti-Arf5 mAb 1B4 was 326	
from Abnova. Mouse anti-β-tubulin mAb TUB 2.1 was from Sigma. Mouse anti-GFP mAb 327	
was from Roche. Peroxidase-conjugated secondary antibodies and cyanine 3-conjugated goat 328	
anti-mouse IgG were from Jackson Immunoresearch.  329	
Cell culture.  Huh-7 [32] and R1 [24] cells were grown at 37°C in Dulbecco’s modified 330	
Eagle’s medium (DMEM), high glucose modification, supplemented with glutamax-I and 331	
10% FCS.  332	
HCV.  The virus JFH1-CSN6A4 used in this study was produced as previously described [5]. 333	
For infection assays, cells were infected for 2 hours at 37°C, and fixed with cold methanol at 334	
30 hpi. 335	
Adenovirus.  A recombinant defective adenovirus expressing a green fluorescent protein 336	
(GFP) was as previously described [24]. Cells were infected for 1 hour at 37°C, and fixed for 337	
20 minutes with PFA 3% at 16 hpi. 338	
SINV.  A recombinant Sindbis virus expressing HCV E1 glycoprotein was as previously 339	
described [33]. Cells were infected for 1 hour at 37°C, and fixed with cold methanol at 6 hpi. 340	
YFV.  Yellow fever virus strain 17D was obtained from Dr Philippe Desprès (Institut Pasteur 341	
de Paris). Cells were infected for 1 hour at 37°C, and fixed with PFA 3% at 24 hpi. 342	
HCoV-229E.  A recombinant human coronavirus 229E expressing GFP [34] was provided by 343	
Dr Volker Thiel (University of Bern, Swiss). Cells were infected for 1 hour at 37°C, and fixed 344	
with PFA 3% at 12 hpi. 345	
CVB4.  Coxsackievirus B4 strain E2 (CVB4) was previously provided by Dr Ji-Won Yoon 346	
(Julia McFarlane Diabetes Research Center, Calgary, Alberta, Canada). CVB4 suspensions 347	
were prepared and titred as described [35]. Cells were infected for 1 hour at 37°C, and fixed 348	
with cold methanol at 6 hpi. 349	
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Infection assays.  Huh-7 cells grown on glass coverslips or in 96-well plates were incubated 350	
at 37°C for 1 or 2 hours (depending on the virus) in the presence of the virus. For each virus, 351	
the viral stocks were diluted so as to obtain 20 to 40% of infected cells in control conditions. 352	
Cells were fixed at a time that allows for a clear detection of infected cells vs. non-infected 353	
cells, and avoids the detection of reinfection events, thus limiting the analysis to a single 354	
round of infection. Cells were fixed for 20 min with 3% PFA or for 1 min with cold methanol 355	
at -20°C. Cells were then rinsed with PBS and processed for immunofluorescence as 356	
previously described [36] using specific primary mouse antibodies to HCV E1 (for both HCV 357	
and SINV), YFV E, GFP (for HCoV-229E) or VP1 (for CVB4) followed by a cyanine-3-358	
conjugated goat anti-mouse IgG secondary antibody for the detection of infected cells. Nuclei 359	
were stained with DAPI. Immunostained cells were observed with a Zeiss Axiophot 360	
microscope equipped with a 10×-magnification objective. Fluorescent signals were collected 361	
with a Coolsnap ES camera (Photometrix). For each well or coverslip, a series of images of 362	
randomly picked areas were automatically recorded using the Metamorph software. Cells 363	
labeled with anti-virus mAbs were counted as infected cells. The total number of cells was 364	
obtained from DAPI-labeled nuclei. Infected cells and nuclei were automatically counted 365	
using a macro written in the ImageJ software. Infections were scored as the ratio of infected 366	
over total cells. Data are presented as the percentage of infection relative to the control 367	
condition. 368	
Drug treatments.  BFA and GCA were dissolved in DMSO, aliquoted and kept at -20°C. For 369	
infection assays with SINV and CVB4, cells were incubated with BFA or GCA at the 370	
indicated concentrations during virus inoculation and up to 6 hpi. For infection assays with 371	
HCV, YFV, adenovirus and HCoV-229E, cells were incubated with BFA or GCA at the 372	
indicated concentrations during virus inoculation and up to 8 hpi. The medium was then 373	
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removed; the cells were rinsed twice with PBS and returned to a drug-free medium until the 374	
end of the assay. For each experiment, a control condition with DMSO was included.  375	
RNA interference.  RNA interference experiments were performed as previously described 376	
[23]. siRNAs were obtained from Dharmacon. For Arf3, Arf4 and Arf5, pools of 4 siRNA 377	
were used. For Arf1, a mix of 2 individual siRNAs (J-011580-05-0005 & J-011580-08-0005) 378	
was used to avoid off-target effects resulting from the use of the pool of 4 siRNAs [23]. The 379	
control siRNA was the non-targeting siRNA #1 (D-001810-01-20).  Briefly, cells were 380	
transfected with siRNAs at 20 nM using lipofectamine RNAi MAX (Life Technologies). The 381	
cells were passed the day after and infected at 3 days post-transfection. 382	
Generation of knock out cells.  Arf genes were invalidated in Huh-7 cells using the CRISPR-383	
Cas9 technology. Guide RNA sequences were selected with the help of the CRISPR design 384	
tool at http://crispr.mit.edu/ and inserted into pX330-U6-Chimeric_BB-CBh-hSpCas9, a gift 385	
from Feng Zhang (Addgene plasmid # 42230). Selected target sequences for sgRNA design 386	
were CTTAAGCTTGTAGAGGATCG for Arf1.1, GATCCTCTACAAGCTTAAGC for 387	
Arf1.2, ATCCTCTACAAGCTTAAGCT for Arf1.3, GGAGATAGTGAGGCCCATGG for 388	
Arf4.1 and GAAGATCCGCGAAAAGAGCG for Arf5.1 KO cell lines. Constructs were 389	
generated as described [37]. Sub-confluent Huh-7 cells grown in 6-well plates were 390	
transfected with 1 µg of CRISPR-Cas9 construct and 50 ng of pPuro using the TransIT-LT1 391	
transfection reagent (Mirus). Two days later, transfected cells were selected with puromycin 392	
at 5 µg/ml during 4 days. The puromycin-containing medium was renewed every day. After 4 393	
days of selection, almost all the cells from control transfections with no pPuro plasmid were 394	
dead. Selected cells were then expanded in puromycin-free medium. The residual expression 395	
of targeted protein was measured using immunoblotting.  396	
Immunoblotting.  Cells were rinsed 3 times with cold PBS, and lysed at 4°C for 20 min in a 397	
buffer containing 50 mM TrisCl, pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% Triton- X, 0.1% 398	
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SDS, 1 mM PMSF, and a mix of protease inhibitors. Insoluble material was removed by 399	
centrifugation at 4°C. The protein content was determined using a bicinchoninic acid assay 400	
(Sigma). The proteins were then resolved by SDS-PAGE and transferred onto nitrocellulose 401	
membranes (Hybond-ECL; Amersham) using a Trans-Blot apparatus (Bio-Rad). Proteins of 402	
interest were revealed with specific primary antibodies, followed by species-specific 403	
secondary antibodies conjugated to peroxidase. Proteins were visualized using enhanced 404	
chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate from Thermofischer 405	
Scientific). The signals were recorded using a LAS 3000 apparatus (Fujifilm). Quantification 406	
of unsaturated signals was carried out using the gel quantification function of ImageJ. 407	
Viability assay.  An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-408	
sulfophenyl)-2H-tetrazolium]-based viability assay (CellTiter 96 aqueous nonradioactive cell 409	
proliferation assay from Promega) was conducted as recommended by the manufacturer using 410	
sub-confluent cell cultures grown in 96-well plates. 411	
Statistical analysis. Statistical analysis was performed using the software Prism. The 412	
significance between groups was determined by one-way ANOVA and a Dunnett post-hoc 413	
test. Only significant p-values are indicated by the asterisks above the graphs. 414	
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FIGURE LEGENDS 541	
Figure 1. Brefeldin A sensitivity of viral infections.  (a) Huh-7 cells were infected in the 542	
presence of indicated BFA concentrations. Infections were quantified by immunofluorescence 543	
assay and expressed as percentage of controls with no BFA. Error bars represent the standard 544	
deviation for 3 independent experiments. (b) Huh-7 cells were incubated with indicated BFA 545	
concentrations for 6h (BFA 6h) or for 8h followed by 22h without BFA (BFA 8h / DMEM 546	
22h), and cell viability was assessed using an MTS assay. Error bars represent the standard 547	
deviation for 3 independent experiments. *, **, and *** mean p-values below .05, .01, and 548	
.001, respectively. 549	
 550	
Figure 2. GBF1 requirement for viral infections.  (a) R1 cells were infected in the presence 551	
of indicated BFA concentrations. Infections were quantified by immunofluorescence assay 552	
and expressed as percentage of controls with no BFA. Error bars represent the standard 553	
deviation for 3 independent experiments. (b) Huh-7 cells were infected in the presence of 50 554	
µM GCA or 0.1% DMSO. Infections were quantified by immunofluorescence assay and 555	
expressed as percentage of DMSO controls. Error bars represent the standard deviation for 3 556	
independent experiments.  (c) Huh-7 cells were incubated with indicated GCA concentrations 557	
for 6h (GCA 6h) or for 8h followed by 22h without GCA (GCA 8h / DMEM 22h), and cell 558	
viability was assessed using an MTS assay. Error bars represent the standard deviation for 3 559	
independent experiments. *, **, and *** mean p-values below .05, .01, and .001, respectively. 560	
 561	
Figure 3. Brefeldin A inhibits a post-entry step.  Huh-7 cells were infected in the presence 562	
of 1 µg/ml BFA or 0.02% DMSO during (entry) and/or after (post-entry) virus inoculation, as 563	
indicated. Infections were quantified by immunofluorescence assay and expressed as 564	
percentage of controls with no BFA. The data are the means of 2 independent experiments.  565	
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 566	
Figure 4. Impact of siRNA-mediated Arf depletion on viral infections.  (a) Specificity of 567	
anti-Arf mAbs probed on lysates of Huh-7 cells expressing the proteins indicated above the 568	
blots. (b, c) Specificity of siRNA-mediated depletions. Huh-7 cells were transfected with 569	
indicated siRNAs. Arf proteins expression was monitored by immunoblotting at 3 days post-570	
transfection (b), and the bands were quantified (c). Results are expressed as percentages of 571	
control non-targeting (siNT1) siRNA. Error bars represent the standard deviation for 3 572	
independent experiments. (d, e) Huh-7 cells were transfected with indicated siRNAs (d) or 573	
siRNA pairs (e) and infected at 3 days post-transfection. Infections were quantified by 574	
immunofluorescence assay and expressed as percentage of control siNT1-transfected cells. 575	
Error bars represent the standard deviation for 6 independent experiments. (f) Cell viability of 576	
siRNA-transfected Huh-7 cells probed at 3 days post-transfection using an MTS assay and 577	
expressed as a percentage of control siNT1-transfected cells. Error bars represent the standard 578	
deviation for 3 independent experiments. *, **, and *** mean p-values below .05, .01, and 579	
.001, respectively. (g) Huh-7 cells were transfected with indicated siRNA pairs and infected 580	
with CVB4 at 3 days post-transfection. The expression of VP1, Arf proteins and tubulin was 581	
monitored by immunoblotting. 582	
 583	
Figure 5. Viral infections of ArfKO cell lines.  Arf5KO (5.1), Arf4KO (4.1) and Arf1KO 584	
(1.1; 1.2 and 1.3) cell lines were generated using the CRISPR-Cas9 technology. A control cell 585	
line was generated with no sgRNA. (a, b) Arf proteins expression was monitored by 586	
immunoblotting (a) and the bands were quantified (b). Results are expressed as percentages 587	
relative to the control cell line. The data are the means of 2 independent experiments. (c) KO 588	
cells were infected with indicated viruses. Infection were quantified by immunofluorescence 589	
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assay and expressed as percentage of control KO cells. The data are the means of 2 590	
independent experiments. 591	
 592	
Figure 6. Impact of siRNA-mediated Arf4 depletion in Arf5KO cells on viral infections.  593	
Control and Arf5KO cell lines were transfected with siRNAs to Arf4 or Arf5 or control non-594	
targeting siNT1. At 3 days post-transfection, (a) the cell viability was measured using an 595	
MTS assay, (b) Arf4 and Arf5 expression was monitored by immunoblotting, and (c) the cells 596	
were infected with indicated viruses. Infections were quantified by immunofluorescence assay 597	
and expressed as percentage of control siRNA (NT1)-transfected control cells. Error bars 598	
represent the standard deviation for 3 independent experiments. *, **, and *** mean p-values 599	
below .05, .01, and .001, respectively. 600	
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